Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 1 2

Status

Completed 2Terminated 1Active not recruiting 1

Sponsor Class

OTHER 6NIH 4INDUSTRY 4OTHER_GOV 1

Study Type

Interventional 4

Sponsor

Cancer Type

Tumor-Agnostic 2Dermatologic 2Other hematologic neoplasm 1

Conditions

Melanoma 8Multiple Myeloma 6Hematologic Neoplasms 6Lymphoma 5Neoplasm Metastasis 4Thyroid Neoplasms 2Glioma 2Cholangiocarcinoma 2Carcinoma, Non-Small-Cell Lung 2Carcinoma, Hepatocellular 2Breast Neoplasms 2Bile Duct Neoplasms 2Uveal Melanoma 1Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Thyroid Cancer, Papillary 1Stomach Neoplasms 1Rectal Neoplasms 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neurofibromatosis 1 1Lung Neoplasms 1Leukemia, Myelomonocytic, Juvenile 1Leukemia, Myeloid, Acute 1Klatskin Tumor 1Hemangioendothelioma, Epithelioid 1Glioblastoma 1

Interventions

Specimen Handling 40Biopsy 39Magnetic Resonance Spectroscopy 31Cyclophosphamide 21aldesleukin 20fludarabine 16fludarabine phosphate 13Leucovorin 12Fluorouracil 12Interleukin-2 11Paclitaxel 9Melphalan 9Oxaliplatin 8trastuzumab deruxtecan 7Irinotecan 7X-Rays 6Taxes 6Nivolumab 6olaparib 5Ipilimumab 5CTLA-4 Antigen 5trametinib 4Neoadjuvant Therapy 4Floxuridine 4Doxorubicin 4Chemotherapy, Adjuvant 4Carboplatin 4veliparib 3talazoparib 3pembrolizumab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
NIH × Neoplasm Metastasis × trametinib × Clear all
NCT02079740 2026-04-29

Trametinib and Navitoclax in Treating Patients With Advanced or Metastatic Solid Tumors

National Cancer Institute (NCI)

Phase 1/2 Active not recruiting
96 enrolled 30 charts
Tumor-Agnostic

Neoplasm Metastasis

NCT02070549 2025-02-13

Trametinib in Treating Patients With Advanced Cancer With or Without Hepatic Dysfunction

National Cancer Institute (NCI)

Phase 1 Completed
46 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT01902173 2025-01-14

Uprosertib, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer

National Cancer Institute (NCI)

Phase 1/2 Completed
27 enrolled 16 charts
DermatologicOther hematologic neoplasm

Melanoma, Neoplasm Metastasis, Hematologic Neoplasms

NCT02097225 2024-10-16

Onalespib, Dabrafenib, and Trametinib in Treating Patients With BRAF-Mutant Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

National Cancer Institute (NCI)

Phase 1 Terminated
22 enrolled 21 charts
Dermatologic

Melanoma, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡